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A B S T R A C T
Patients with AIDS are often severely immunocompromised. These patients commonly develop
opportunistic infections such as oropharyngeal candidiasis whose treatment may prove to be difficult.
Caspofungin belongs to a new class of antifungal agents that have a different mode of action to azoles
and polyenes. This new agent is the first inhibitor of fungal glucan synthesis to receive approval for the
treatment of mucosal and invasive candidiasis and invasive aspergillosis. Caspofungin is well-tolerated
and represents a substantial improvement over existing therapeutic options for patients prone to azole-
resistant candida infection or who cannot tolerate amphotericin B.
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Patients with AIDS tend to be severely immuno-
compromised and to develop opportunistic infec-
tions such as oropharyngeal candidiasis. The
Adult and Adolescent Spectrum of Disease Pro-
ject found that although there has been a decrease
in the incidence of many of the infectious diseases
that afflict HIV-positive patients in the USA,
oesophageal candidiasis remains the third most
common opportunistic infection in this patient
population [1]. Patients who do not achieve viral
suppression and immune reconstitution with
antiretroviral therapy thus remain at high risk of
opportunistic infection.
Treatment of oropharyngeal candidiasis in
HIV-infected patients can be challenging. Azoles
are safe and effective agents for the treatment of
oesophageal candidiasis and have gradually
replaced amphotericin B (AmBD). However,
resistance to azoles is now becoming common
[2–5]. Although many Candida strains are suscept-
ible to AmBD, patients with Candida glabrata or
Candida krusei infection may require high doses
[2]. This represents a problem, particularly in
severely immunocompromised patients, because
AmBD is known to cause a very high incidence of
side effects and toxicity. Newer antifungals, such
as voriconazole and caspofungin, have a broader
spectrum of activity that includes fluconazole-
resistant Candida spp. The use of these new
options should therefore be considered for the
treatment of refractory oropharyngeal candidia-
sis.
As an illustration of the use of these agents, a
patient in our hospital with long-standing AIDS
was diagnosed with azole-refractory oropharyn-
geal and oesophageal candidiasis and intolerance.
The patient was a 43-year-old caucasian male
with AIDS stage C3 for 15 years, who had
suffered from several episodes of opportunistic
infections. Although fluconazole was used
prophylactically because of severe immunode-
ficiency, the patient developed recurrent oropha-
ryngeal candidiasis. The patient remained
severely immunocompromised, with a CD4 cell
count ranging between 9 and 3 ⁄mm3, and a viral
load between 60 876 and 25 302 HIV RNA
copies ⁄mL despite the antiretroviral treatment.
In 2002, a culture from an oropharyngeal swab
revealed Candida albicans (AmBD and voricon-
azole-susceptible, and fluconazole and itraconaz-
ole-resistant) and C. glabrata (AmBD and
voriconazole-susceptible, fluconazole-intermedi-
ate, and itraconazole-resistant).
The patient was treated with oral voricona-
zole 200 mg twice-daily. After treatment for
9 months, a severe papular, pruriginous erythema
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developed on the dorsal side of the hands and the
neck. The patient also experienced an episode of
photosensitivity after exposure to the sun. A skin
biopsy was performed, and the histological exami-
nation showed a lichenoid dermatoepidermitis.
Voriconazole treatment was discontinued, as it
was believed to be the cause of the rash. Follow-
ing recurrence of severe oropharyngeal and oeso-
phageal candidiasis, the patient was treated with
intravenous AmBD 50 mg by continuous infusion
for 24 h. This induced acute renal impairment: the
creatinine levels increased from 71 lmol ⁄L before
AmBD administration to 184 lmol ⁄L. Therefore,
treatment with AmBD was discontinued and the
patient was switched to intravenous caspofungin,
administered once-daily with a loading dose of
70 mg followed by 50 mg ⁄day. The patient com-
pleted treatment for 1 week, with complete reso-
lution of clinical signs. Four days after the switch
to caspofungin, the creatinine level returned to a
normal value.
Previous use of azoles and CD4 counts of
< 50 ⁄mm3 are associated with azole-resistant can-
dida infections [6]. The patient described above
was severely immunocompromised, had a history
of azole prophylaxis, and developed an oropha-
ryngeal and oesophageal candidiasis that was
unresponsive to therapy with classical azoles.
Treatment with voriconazole was not tolerated
because of allergic reactions, and the use of
AmBD induced renal toxicity.
Caspofungin belongs to the echinocandins, a
novel class of antifungal agents that have a
different mode of action from that of azoles and
polyenes. Echinocandins inhibit b-1,3-glucan syn-
thesis in the fungal cell wall, while other agents act
on ergosterol in the fungal cell membrane [7,8].
Caspofungin exhibits in-vitro activity even against
Candida strains resistant to azoles [7,9,10]. It has
also been shown to be effective and well-tolerated
in patients with fluconazole-resistant oesophageal
candidiasis [11,12]. In a large study of predomin-
antly HIV-positive patients with oesophageal can-
didiasis, caspofungin was found to be as effective
as AmBD, but better tolerated [13,14]. This new
agent is the first inhibitor of fungal glucan syn-
thesis to receive approval for the treatment of
mucosal and invasive candidiasis and invasive
aspergillosis [15]. It may represent a substantial
improvement over existing therapy, particularly
for patients with AIDS, who tend to be prone to
candida infections resistant to azoles, and in
immunocompromised patients who may not be
able to tolerate AmBD. In patients with invasive
candidiasis, success has been observed in 73%
of caspofungin recipients and in 62% of AmBD
recipients, while adverse events occurred signifi-
cantly more frequently among AmBD recipients
than among caspofungin recipients [16].
As there is no evidence of in-vitro antagonism
when caspofungin is used in combination with
other antifungal agents, it is an important agent
for combination therapy, a strategy already used
by some clinicians for the treatment of invasive
aspergillosis [17–19]. However, the precise corre-
lation between the in-vitro interaction data and
the clinical outcome currently remains unknown,
and further clinical investigations are needed to
determine this.
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